We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SaaS Business Update

7 Mar 2018 07:00

RNS Number : 9062G
Instem plc
07 March 2018
 

7 March 2018

Instem plc

 

("Instem" or the "Company")

 

SaaS Business Update

 

Growing demand for Instem's Software-as-a-Service ("SaaS") delivery model

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that one of the world's largest chemical products companies is the latest customer to adopt the Company's market leading SaaS delivery model for accessing its solutions via the Instem Cloud. Annual recurring revenue from this client will immediately increase by over 40%.

 

The growing shift towards the SaaS based revenue model will see a continued improvement of earnings visibility for Instem and will ultimately deliver an expansion in operating margins in-line with similar cloud-based delivery models.

 

Originally developed to attract new clients, this latest client to adopt the Company's SaaS approach has been using Instem's Provantis® software for more than 12 years and represents the growing trend to move from on-site installations to the Company's highly secure, cloud-based SaaS offering.

 

 

Instem's SaaS Platform

Instem's SaaS clients enjoy a reduced IT burden, flexibility and scalability to meet their changing needs, giving them faster access to new product releases and high quality shared services that in turn deliver an enhanced customer experience in terms of lower total cost of ownership, rapid implementation and high reliability.

 

Instem's professionally managed online platforms are run from centralised state-of-the-art third-party data centres, which can be accessed from any location that offers connectivity to the Internet, 24 hours a day, seven days a week, and are currently being used every day by drug developers, contract research organisations, universities, research institutes and government agencies around the world.

 

 

SaaS Impact on Quality of Earnings

The 40% increase in recurring revenue from one client is typical of Instem clients converting from on premise to SaaS deployment. With £3.4m of existing SaaS revenue and £9.6m of non-SaaS based recurring revenue, procured on an annual basis, reported for the 12 months to 30 June 2017, there remains a significant opportunity to achieve material increases in SaaS based revenue recognition over the next few years as clients make the transition.

 

ISO 27001

With an ever-increasing volume of high-value client data under its control, Instem has been independently certified to the international standard for information security management systems, ISO 27001. This is another unique differentiator for Instem in a market environment that has become highly focused on information security. The newly awarded certification to ISO 27001 is also a significant component in ensuring both internal and client compliance with EU General Data Protection Regulation ('GDPR') which becomes law on 25 May 2018, which we believe is another reason why customers are switching to Instem's SaaS cloud delivery platform.

 

Phil Reason, CEO of Instem plc, commented: "The strategic process of migrating clients from on-site installations to our market leading SaaS model continues apace. This latest agreement with a leading chemical client sees Instem deploy its Provantis® product from its own secure cloud services environment, as opposed to the client's own data centre, thereby reducing their cost of ownership while improving Instem's software deployment and management efficiencies."

 

"The transition to SaaS across the regulatory life sciences industry has been quickening in recent months after initial concerns over data security and the generally conservative nature of the participants. However, both existing clients and new prospects are now fully recognising Instem's leadership in this area and with GDPR coming into effect in May of this year we anticipate strong growth in SaaS revenue."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

Rachel Hayes

Walbrook Financial PR

+44 (0) 20 7933 8000

Paul Cornelius

instem@walbrookpr.com

Sam Allen

Helen Cresswell

 

About Instem

 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

 

About Provantis®

Provantis® is a modern, fully integrated Windows-based system for organisations engaged in non-clinical evaluation studies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDJFMBTMBMMTMP
Date   Source Headline
1st Sep 20217:00 amRNSAcquisition of PDS Pathology Data Systems
19th Jul 20217:00 amRNSHalf Year Trading Update
16th Jun 20213:30 pmRNSHolding(s) in Company
14th Jun 20217:00 amRNSNotice of Capital Markets Day
27th May 20213:48 pmRNSResult of AGM
20th May 20214:56 pmRNSHolding(s) in Company
11th May 202111:52 amRNSHolding(s) in Company
5th May 20217:32 amRNSHolding(s) in Company
20th Apr 20214:45 pmRNSExercise of Options, Issue of Equity and TVR
19th Apr 202112:10 pmRNSGrant of Options
19th Apr 20217:00 amRNSHolding(s) in Company
15th Apr 20215:45 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSFinal Results
1st Apr 20214:30 pmRNSCompletion of Acquisition of d-wise
30th Mar 20217:00 amRNSNotice of Results
22nd Mar 20217:00 amRNSAcquisition of d-wise and Investor Presentation
1st Mar 20217:00 amRNSAcquisition of The Edge
14th Jan 20217:00 amRNSTrading Update
15th Dec 20207:00 amRNSNew Business Update
27th Oct 20207:00 amRNSInvestor Presentation
28th Sep 20207:00 amRNSHalf-year Report
15th Sep 20207:00 amRNSNotice of Results
9th Sep 202012:14 pmRNSHolding(s) in Company
13th Aug 202012:40 pmRNSHolding(s) in Company
22nd Jul 202010:27 amRNSHolding(s) in Company
21st Jul 202011:53 amRNSHolding(s) in Company
20th Jul 20205:37 pmRNSHolding(s) in Company
20th Jul 20205:36 pmRNSHolding(s) in Company
20th Jul 202011:52 amRNSHolding(s) in Company
20th Jul 20207:00 amRNSHalf Year Trading Update
17th Jul 20203:42 pmRNSHolding(s) in Company
17th Jul 202012:38 pmRNSHolding(s) in Company
17th Jul 202012:34 pmRNSHolding(s) in Company
17th Jul 20209:15 amRNSDirector/PDMR Dealings
16th Jul 202012:27 pmRNSResult of General Meeting, Issue of Equity and TVR
8th Jul 20207:00 amRNSInvestor Communications
3rd Jul 20203:54 pmRNSHolding(s) in Company
30th Jun 20205:33 pmRNSPublication of Circular and Notice of GM
30th Jun 20202:56 pmRNSResult of AGM
26th Jun 20202:00 pmRNSResult of Placing
26th Jun 20207:00 amRNSProposed Placing
3rd Jun 20207:01 amRNSContract Win
3rd Jun 20207:00 amRNSFinal Results
29th May 20207:00 amRNSNotice of Results
25th Mar 20207:00 amRNSUpdate to Results Announcement Date
24th Feb 20207:00 amRNSNotice of Results
13th Feb 202010:40 amRNSExercise of Options/Issue of Equity
13th Jan 20207:00 amRNSTrading Update
16th Dec 20195:48 pmRNSExercise of Options and Total Voting Right
18th Nov 201910:40 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.